1,905 Madrigal Pharmaceuticals, Inc. $MDGL Shares Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lowered its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 37.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,164 shares of the biopharmaceutical company’s stock after selling 1,905 shares during the period. Illinois Municipal Retirement Fund’s holdings in Madrigal Pharmaceuticals were worth $1,595,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in MDGL. Persistent Asset Partners Ltd purchased a new stake in shares of Madrigal Pharmaceuticals during the second quarter worth $29,000. Global Retirement Partners LLC purchased a new position in Madrigal Pharmaceuticals in the second quarter valued at $34,000. Provenance Wealth Advisors LLC purchased a new position in Madrigal Pharmaceuticals in the third quarter valued at $69,000. Root Financial Partners LLC acquired a new position in Madrigal Pharmaceuticals during the 3rd quarter worth $82,000. Finally, GAMMA Investing LLC grew its stake in Madrigal Pharmaceuticals by 35.4% during the 2nd quarter. GAMMA Investing LLC now owns 172 shares of the biopharmaceutical company’s stock worth $92,000 after purchasing an additional 45 shares in the last quarter. 98.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on MDGL. Barclays cut their price target on Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Truist Financial reiterated a “buy” rating and issued a $743.00 price objective (up from $709.00) on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 4th. Canaccord Genuity Group boosted their price objective on Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research note on Thursday, October 15th. Finally, Wolfe Research upgraded shares of Madrigal Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $605.00 target price on the stock in a research note on Tuesday, August 4th. Fourteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Madrigal Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $706.87.

Read Our Latest Stock Analysis on MDGL

Madrigal Pharmaceuticals Stock Down 0.8%

MDGL stock opened at $423.96 on Tuesday. Madrigal Pharmaceuticals, Inc. has a one year low of $353.54 and a one year high of $615.00. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.78 and a current ratio of 3.05. The company has a fifty day moving average of $473.38 and a 200-day moving average of $495.43. The stock has a market capitalization of $9.85 billion, a PE ratio of -70.90 and a beta of -0.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, topping the consensus estimate of ($1.09) by $2.92. The business had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative return on equity of 27.08% and a negative net margin of 10.89%. During the same quarter in the previous year, the company earned ($5.08) EPS. As a group, analysts expect that Madrigal Pharmaceuticals, Inc. will post -2.08 EPS for the current year.

Insider Activity at Madrigal Pharmaceuticals

In other news, Director Bros. Advisors Lp Baker purchased 76,140 shares of the firm’s stock in a transaction on Friday, November 6th. The shares were bought at an average cost of $384.32 per share, with a total value of $29,262,124.80. Following the purchase, the director directly owned 2,040,682 shares of the company’s stock, valued at approximately $784,274,906.24. This trade represents a 3.88% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel Shannon Kelley sold 1,077 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $400.00, for a total transaction of $430,800.00. Following the sale, the general counsel owned 10,397 shares in the company, valued at approximately $4,158,800. This trade represents a 9.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 12,660 shares of company stock valued at $6,670,042 over the last quarter. Insiders own 17.60% of the company’s stock.

Madrigal Pharmaceuticals Profile

(Free Report)

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. The company is headquartered in Conshohocken, Pennsylvania. Its lead product, Rezdiffra (resmetirom), is a thyroid hormone receptor-beta agonist. The U.S. Food and Drug Administration approved Rezdiffra in 2024 for use with diet and exercise in adults with noncirrhotic MASH and moderate-to-advanced liver fibrosis.

Further Reading

Want to see what other hedge funds are holding MDGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report).

Institutional Ownership by Quarter for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.